ir. R.S. Rosendaal

ir. R.S. Rosendaal

Full Professor
ir. R.S. Rosendaal
  • Pulmonology Research 2
  • Onderzoek



Dr. J.M. Beekman obtained a PhD in molecular immunology in 2004, and performed multiple post docs in molecular and cell biology within various immunological settings. In October 2010, he became principle investigator at the UMC Utrecht, and started a novel translational research line focusing on developing novel therapeutic strategies for cystic fibrosis, a genetic disease characterized by aberrant ion and fluid homeostasis at mucosal surfaces leading to chronic infection and inflammation and early death around the 3rd to 4th decade of life.


‘People with chronic diseases living healthy lives: I strive to create breakthrough solutions for clinical needs of people with chronic diseases by scientific research that focuses on the development of novel diagnostic or therapeutic approaches. This requires a multidisciplinary approach in which basic and clinical research is aligned, and integrated with needs of patients, the private sector and regulatory authorities. Currently, I am particularly proud of leading a team that developed a highly innovative diagnostic assay that enables individualized therapy for people with cystic fibrosis that lead to direct clinical impact for people within 4 years after the initial discovery.’

Side Activities

Professional activities

2021    Co-founder Fair Therapeutics 

2020    Member selection committee for “3V-stimuleringsfonds” UU and UMCU     

2019    Vice-president organizing committee European CF society conference 2022  

2018    PhD Committee and opponent of Franz Shan Brunel, University of Aberdeen, UK 

2017    PhD Committee and opponent of Karen Schelde, University of Aarhus, Denmark 

2017    Consultant at CFF Theratyping workshop  

2016    European CF society basic science working group – vice coordinator 

2016    Grant reviewer Canadian Foundation for Innovation 

2016    Grant reviewer Cystic Fibrosis Research, Inc. (CFRI) 

2016    Grant reviewer German CF society 

2016    Advisor for future funding of UK Cystic Fibrosis Trust (Research Sandpit Workshop, 8-9 Feb) 

2015     Grant reviewer SRC grant application Cystic Fibrosis Trust (UK) 

2015     Avicenna Roadmap Authoring Team – A strategy for in silico clinical trials 

2013 –  Editorial board member of Rare Diseases

2013 –  Editorial board member of PlosOne

2013 –  Annual candidate selection committee for Eureka Institute of Translational Medicine

2010 –   Reviewer for various journals including Cell, Nature Medicine, Nature Communications, PlosOne, Journal of Immunological Methods, Journal of Leukocyte Biology, Molecular Immunology, Journal of Medical Genetics, Journal of Cystic Fibrosis


2019-     UWE, collaboration Utrecht-Wageningen-Eindhoven

2019-     Membership transition-team for animal-free innovation Utrecht

2014 –    European Respiratory Society

2010 –    European Cystic Fibrosis Society

2011 –    Eureka Institute for Translational Medicine

2000 –    Dutch Society of Immunology (NVVI


Potential Conflicts of Interest

Dr Beekman has regular interactions with commercial parties including pharmaceutical companies, and performs academic associated research mostly in public-private partnerships or fee-for-service activities with such companies. Beekman was PI on grants with Galapagos, Proteostasis, and Eloxx Pharmaceuticals that led to major funding contributions from these companies to UMCU (>100K). Other companies provided in kind contributions. He is inventor of a patent (20210333266) that was licensed to Hubrecht Organoid Technology and he received personal royalties from 2017 onward (max annual income <3000 euros up to 2021) from the Royal Dutch Academy of Sciences and Arts. Dr Beekman has received personal support for preparation of meetings or consultancy (all below 2200 euro per event), or reimbursement of traveling and lodging costs for participating in industry-sponsored educational meeting (all below €2200 per event). He co-founded FAIR therapeutics BV in 2021 and has a minority shareholders position.

Research Output (99)

In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center

Rümke Lidewij W, Groenveld Femke C, van Os Yvonne M G, Praest Patrique, Tanja Anniek A N, de Jong Dorien T C M, Symons Jori, Schuurman Rob, Reinders Tessa, Hofstra L Marije, Nierkens Stefan, Thijsen Steven F T, Heron Michiel, Lebbink Robert-Jan, Beekman Jeffrey M, Nijhuis Monique, Wensing Annemarie M J Jan 2022, In: Open forum infectious diseases. 9 , p. 1-6

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators

Muilwijk Danya, Bierlaagh Marlou, van Mourik Peter, Kraaijkamp Jasmijn, van der Meer Renske, van den Bor Rutger, Heijerman Harry, Eijkemans René, Beekman Jeffrey, van der Ent Kors 16 Dec 2021, In: Journal of Personalized Medicine. 11 , p. 1-12

Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids

Geurts Maarten H., de Poel Eyleen, Pleguezuelos-Manzano Cayetano, Oka Rurika, Carrillo Léo, Andersson-Rolf Amanda, Boretto Matteo, Brunsveld Jesse E., van Boxtel Ruben, Beekman Jeffrey M., Clevers Hans Oct 2021, In: Life Science Alliance. 4

CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy

de Poel Eyleen, Spelier Sacha, Korporaal Ricardo, Lai Ka Wai, Boj Sylvia F., Conrath Katja, van der Ent Cornelis K., Beekman Jeffrey M. 15 Sep 2021, In: Frontiers in Molecular Biosciences. 8

A new era for people with cystic fibrosis

Bierlaagh Marlou C., Muilwijk Danya, Beekman Jeffrey M., van der Ent Cornelis K. Sep 2021, In: European Journal of Pediatrics. 180 , p. 2731-2739 9 p.

Breast development in a 7 year old girl with CF treated with ivacaftor:An indication for personalized dosing?

Jeyaratnam Joshena, van der Meer Renske, Berkers Gitte, Heijerman Harry Gm, Beekman Jeffrey M, van der Ent Cornelis K 23 Jun 2021, In: Journal of Cystic Fibrosis. 20 , p. e63-e66

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Berkers Gitte, van der Meer Renske, van Mourik Peter, Vonk Annelotte M, Kruisselbrink Evelien, Suen Sylvia Wf, Heijerman Harry Gm, Majoor Christof J, Koppelman Gerard H, Roukema Jolt, Janssens Hettie M, de Rijke Yolanda B, Kemper E Marleen, Beekman Jeffrey M, van der Ent Cornelis K, de Jonge Hugo R Nov 2020, In: Journal of Cystic Fibrosis. 19 , p. 955-961 7 p.

R117H-CFTR function and response to VX-770 correlate with mRNA and protein expression in intestinal organoids

Van Mourik Peter, van Haaren Paul, Kruisselbrink Evelien, Korkmaz Cemil, Janssens Hettie M., de Winter – de Groot Karin M., van der Ent Cornelis K., Hagemeijer Marne C., Beekman Jeffrey M. Sep 2020, In: Journal of Cystic Fibrosis. 19 , p. 728-732 5 p.

Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids

Vonk Annelotte M, van Mourik Peter, Ramalho Anabela S, Silva Iris A L, Statia Marvin, Kruisselbrink Evelien, Suen Sylvia W F, Dekkers Johanna F, Vleggaar Frank P, Houwen Roderick H J, Mullenders Jasper, Boj Sylvia F, Vries Robert, Amaral Margarida D, de Boeck Kris, van der Ent Cornelis K, Beekman Jeffrey M 19 Jun 2020, In: STAR protocols. 1 31 p.

CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank

Geurts Maarten H., de Poel Eyleen, Amatngalim Gimano D., Oka Rurika, Meijers Fleur M., Kruisselbrink Evelien, van Mourik Peter, Berkers Gitte, de Winter-de Groot Karin M., Michel Sabine, Muilwijk Danya, Aalbers Bente L., Mullenders Jasper, Boj Sylvia F., Suen Sylvia W.F., Brunsveld Jesse E., Janssens Hettie M., Mall Marcus A., Graeber Simon Y., van Boxtel Ruben, van der Ent Cornelis K., Beekman Jeffrey M., Clevers Hans 2 Apr 2020, In: Cell stem cell. 26 , p. 503-510.e7

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not